New Jersey Chapter of AACE 11th Annual Meeting
Welcome, and thank you for attending the New Jersey Chapter of AACE 11th Annual Meeting & Symposium.
The New Jersey Chapter of AACE program committee has worked very hard to provide a relevant activity for the practicing clinical physician and other healthcare providers seeking education with an emphasis in endocrine disease.
This program has been planned to provide pertinent scientific and clinical information to help you achieve the best solutions in the diagnosis and therapeutic management of patients presenting with endocrine disease. Attendees will obtain updates in not only common and uncommon endocrine disorders, but also newer treatment modalities.
Providing exceptional patient care requires continuing high quality education. The American Association of Clinical Endocrinologists (AACE) was founded in 1991 by a visionary group of leaders to serve as the active voice for clinical endocrinologists. The impetus behind AACE's efforts has always been quality and cost-effective patient care for those with endocrine diseases and disorders. We hope that you will find this program of great value to you in your practice.
Endocrinologists, MDs & DOs, advanced practice clinicians and other healthcare professionals interested in the treatment of endocrine disease living or working in New Jersey.
- After participating in a pre-meeting assessment tool, attendees will be able to recognize areas of potential shortcoming and strive to improve knowledge and consequential healthcare practices.
- Discuss the epidemiology, prevalence, and risk factors for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)
- Review use of non-invasive technology available to evaluate the severity of liver disease
- Discuss available and emerging treatments for NASH
- Describe the clinical manifestations of abnormal reductions in adipose tissue mass
- Recognize the pathogenic mechanisms mediating lipoatrophy-associated metabolic abnormalities
- Discuss the therapeutic options to manage lipoatrophic diabetes
- Recognize the challenges that must be met to automate control of blood glucose levels in people with type 1 diabetes
- List the elements of an automated closed-loop bionic pancreas
- Describe the results of recent clinical studies of closed-loop blood glucose control using subcutaneous delivery of insulin and glucagon.
- Describe the gut hormone responses to diet-induced weight loss
- Describe the gut hormone responses to bariatric surgery
- Describe changes in hypothalamic hormones that regulate appetite after weight loss
- Describe the mechanistic basis for the efficacy of tyrosine kinase inhibitors in the treatment of thyroid cancer
- Review current accepted uses of tyrosine kinase inhibitors in the treatment of thyroid cancer
- Provide an update on potential new uses for tyrosine kinase inhibitors in the treatment of thyroid cancer
- Discuss the 3 clinical phenotypes of Primary Hyperparathyroidism
- Review the skeletal manifestations of Primary Hyperparathyroidism
- Review the approach to diagnosis, evaluation, and intervention
- Understanding how proper documentation is linked to quality, optimal and appropriate E&M coding.
- Conceptualize how the E&M documentation correlates to the quality payment program and ACO payments
- The importance of ICD coding relative to E&M, QPP and ACO Optimization
- At the conclusion of the meeting, attendees will be able to measure learning that occurred that will enable the use of new healthcare techniques and practices and to review or confirm existing care modalities.
AT FORRESTAL VILLAGE
201 VILLAGE BOULEVARD
PRINCETON, NJ 08540
Saturday, October 6, 2018
|8:00 – 8:45 AM|
Registration and Continental Breakfast
|8:45 – 9:00 AM|
Welcoming Remarks & Pre-Meeting Assessment
|9:00 – 10:00 AM|
NAFLD and NASH Treatment 2018 and Beyond: Cutting through the fat
|10:00 – 11:00 AM|
Lipoatrophic Diabetes: What can zebras teach us about horses?
|11:00 – 11:30 AM|
|11:30 – 12:30 PM|
The Bionic Pancreas – Non-CME
|12:30 – 12:45 PM|
NJ AACE Business Meeting
|12:45 – 1:45 PM|
|1:45 – 2:45 PM|
|2:45 – 3:15 PM|
|3:15 – 4:15 PM|
The Established and Emergent Roles of Tyrosine Kinase Inhibitors in Thyroid Cancer
|4:15 – 5:15 PM|
Primary Hyperparathyroidism, 2018
|5:15 – 5:30 PM|
|5:30 – 8:00 PM|
Session / Dinner
|5:30 – 6:30 PM|
Optimal Coding for Optimal Reimbursement and Quality Reporting – Non-CME
|6:30 – 8:00 PM|
John P. Bilezikian, MD
Silberberg Professor of Medicine
Vice Chair: International Education and Research
Chief, Emeritus, Division of Endocrinology
Director, Metabolic Bone Diseases Unit
College of Physicians and Surgeons
New York, NY
Edward Damiano, PhD
Professor of Biomedical Engineering at Boston University
President & CEO, Beta Bionics
Dina Halegoua-De Marzio, MD
Assistant Professor of Medicine
Director, Jefferson Fatty Liver Center
Transplant Hepatology Fellowship Program Director
Sidney Kimmel Medical College at Thomas Jefferson University
Douglas J Jorgensen, DO, CPC, FAAO, FACOFP, CAQ
Judith Korner, MD, PhD
Professor of Medicine
Director, Weight Control Center
Columbia University Medical Center
Vice-Chair, American Board of Obesity Medicine
New York, NY
Loren Michel, MD
Head and Neck Medical Oncology
Memorial Sloan Kettering Cancer Center
Ranganath Muniyappa, MD, PhD
Director, NIH Inter-Institute Endocrinology Training Program
Senior Clinician, Diabetes, Endocrinology, and Obesity Branch
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH, Bethesda, MD
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American Association of Clinical Endocrinologists (AACE) and the New Jersey Chapter of AACE. The American Association of Clinical Endocrinologists (AACE) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American Association of Clinical Endocrinologists (AACE) designates this live activity for a maximum of 5.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 5.50 AMA
- 5.50 Attendance